Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model

It is important to examine the cytochrome P450 2C19 (CYP2C19) genetic contribution to drug disposition and responses of CYP2C19 substrates during drug development. Design of such clinical trials requires projection of genotype-dependent in vivo clearance and associated variabilities of the investigational drug, which is not generally available during early stages of drug development, but is essential for CYP2C19 substrates with multiple clearance pathways. This study evaluated the utility of pharmacogenetics-based mechanistic modeling in predicting such parameters. Hepatic CYP2C19 activity and variability within genotypes were derived from in vitro S-mephenytoin metabolic activity in genotyped human liver microsomes (N = 128). These data were then used in mechanistic models to predict genotype-dependent disposition of CYP2C19 substrates (i.e., S-mephenytoin, citalopram, pantoprazole, and voriconazole) by incorporating in vivo clearance or pharmacokinetics of wild-type subjects and parameters of other clearance pathways. Relative to the wild-type, the CYP2C19 abundance (coefficient of variation percentage) in CYP2C19*17/*17, *1/*17, *1/*1, *17/null, *1/null, and null/null microsomes was estimated as 1.85 (117%), 1.79 (155%), 1.00 (138%), 0.83 (80%), 0.38 (130%), and 0 (0%), respectively. The subsequent modeling and simulations predicted, within 2-fold of the observed, the means and variabilities of urinary S/R-mephenytoin ratio (36 of 37 genetic groups), the oral clearance of citalopram (9 of 9 genetic groups) and pantoprazole (6 of 6 genetic groups), and voriconazole oral clearance (4 of 4 genetic groups). Thus, relative CYP2C19 genotype-dependent hepatic activity and variability were quantified in vitro and used in a mechanistic model to predict pharmacokinetic variability, thus allowing the design of pharmacogenetics and drug-drug interaction trials for CYP2C19 substrates.

[1]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[2]  G R Wilkinson,et al.  A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.

[3]  J. Goldstein,et al.  Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[5]  P. Zhao,et al.  Bioavailability Considerations in Evaluating Drug‐Drug Interactions Using the Population Pharmacokinetic Approach , 2011, Journal of clinical pharmacology.

[6]  M. Ingelman-Sundberg,et al.  S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. , 1996, Pharmacogenetics.

[7]  Lang Li,et al.  CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling , 2013, Drug Metabolism and Disposition.

[8]  Y. Sugiyama,et al.  Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. , 2014, Drug metabolism and pharmacokinetics.

[9]  Juanli Zhu,et al.  Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation , 2011, Drug Metabolism and Disposition.

[10]  F. Larsen,et al.  Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects , 1998, European Journal of Clinical Pharmacology.

[11]  Amin Rostami-Hodjegan,et al.  Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure , 2013, European Journal of Clinical Pharmacology.

[12]  C. Alm,et al.  S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin , 1989, Clinical pharmacology and therapeutics.

[13]  K. Fredricson Overø.  Kinetics of citalopram in man; plasma levels in patients. , 1982, Progress in neuro-psychopharmacology & biological psychiatry.

[14]  D. Flockhart,et al.  Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[15]  R. Desnick,et al.  CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. , 2007, Pharmacogenomics.

[16]  A. Mayet,et al.  Genotype-Phenotype Analysis of CYP2C19 in Healthy Saudi Individuals and its Potential Clinical Implication in Drug Therapy , 2013, International journal of medical sciences.

[17]  R. Desnick,et al.  Multi-ethnic Distribution of Clinically Relevant CYP2C Genotypes and Haplotypes , 2012, The Pharmacogenomics Journal.

[18]  J. Paulauskis,et al.  So Many Studies, Too Few Subjects: Establishing Functional Relevance of Genetic Polymorphisms on Pharmacokinetics , 2006, Journal of clinical pharmacology.

[19]  J. Goldstein,et al.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. , 1997, Pharmacogenetics.

[20]  S. Sviri,et al.  Phenotypic‐genotypic analysis of CYP2C19 in the Jewish Israeli population , 1999, Clinical pharmacology and therapeutics.

[21]  K. Overø.  Kinetics of citalopram in man; plasma levels in patients , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[23]  J. Xie,et al.  Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. , 2008, Pharmacogenomics.

[24]  Zhaoqian Liu,et al.  Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[25]  Amin Rostami-Hodjegan,et al.  Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  Min-ting Lin,et al.  [Prevalence of CYP2C19 polymorphisms involved in clopidogrel metabolism in Fujian Han population]. , 2012, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[28]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .

[29]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[30]  Saeed Rezaee,et al.  Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application , 2007, Journal of clinical pharmacology.

[31]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[32]  J. Mega,et al.  Consortium ( CPIC ) guidelines for cytochrome P 450-2 C 19 ( CYP 2 C 19 ) genotype and clopidogrel therapy , 2011 .

[33]  M. Al-Dosari,et al.  CYP2C19 Genetic Polymorphism in Saudi Arabians , 2013, Basic & clinical pharmacology & toxicology.

[34]  Y. Zhang,et al.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. , 1991, British journal of clinical pharmacology.

[35]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[36]  W. Guan,et al.  microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. , 2014, Biochemical and biophysical research communications.

[37]  Amin Rostami-Hodjegan,et al.  Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using in vitro data as an aid to assess study power , 2009, Pharmaceutical statistics.

[38]  T. Guo,et al.  Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. , 2012, Genetic testing and molecular biomarkers.

[39]  X. Chu,et al.  Functional Evaluation of Genetic and Environmental Regulators of P450 mRNA Levels , 2011, PloS one.

[40]  K. Carroll,et al.  The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. , 2004, Toxicology and applied pharmacology.

[41]  J. Weide,et al.  Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients , 2011, The Pharmacogenomics Journal.

[42]  K. Knights,et al.  The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9 , 2008, Drug Metabolism and Disposition.

[43]  W. Haefeli,et al.  CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.

[44]  J. Paulauskis,et al.  Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First‐ and Third‐generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations , 2008, Clinical pharmacology and therapeutics.

[45]  A. de Boer,et al.  The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting , 2012, Pharmacogenetics and genomics.

[46]  Hong-Guang Xie,et al.  Genetic analysis of the S‐mephenytoin polymorphism in a chinese population , 1995, Clinical pharmacology and therapeutics.

[47]  L. Bertilsson,et al.  A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. , 1992, Pharmacogenetics.

[48]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[49]  van der Hoeven Ta,et al.  Preparation and Properties of Partially Purified Cytochrome P-450 and Reduced Nicotinamide Adenine Dinucleotide Phosphate-Cytochrome P-450 Reductase from Rabbit Liver Microsomes , 1974 .

[50]  Hong-Guang Xie,et al.  Differences in the Incidence of the CYP 2 C 19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP 2 C 19 Mutant Allele 1 , 1997 .

[51]  M. Droździk,et al.  CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers , 2012, European Journal of Clinical Pharmacology.

[52]  A. Borobia,et al.  Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. , 2010, European journal of pharmacology.

[53]  Michel Loève,et al.  Probability Theory I , 1977 .

[54]  Doaa A. Elsherbiny,et al.  Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[55]  S. Goutelle,et al.  In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates , 2013, The AAPS Journal.

[56]  P. Hardenbol,et al.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.

[57]  R. Branch,et al.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. , 1985, The Journal of pharmacology and experimental therapeutics.

[58]  R. Branch,et al.  Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital , 1986, Clinical pharmacology and therapeutics.

[59]  M. J. Coon,et al.  Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. , 1974, The Journal of biological chemistry.

[60]  H. Refsum,et al.  Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients , 2008, Clinical pharmacology and therapeutics.

[61]  Zhaoqian Liu,et al.  CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population , 2002, European Journal of Clinical Pharmacology.

[62]  Amin Rostami-Hodjegan,et al.  The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. , 2007, British journal of clinical pharmacology.

[63]  Y. Wing,et al.  Phenotype-genotype Relationship and Clinical Effects of Citalopram in Chinese Patients , 2006, Journal of clinical psychopharmacology.

[64]  Shiew-Mei Huang,et al.  Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions , 2014, Pharmaceutical Research.

[65]  M. Ingelman-Sundberg,et al.  Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. , 2002, Pharmacogenetics.

[66]  T. Edwards,et al.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. , 2004, Pharmacogenomics.